December 12, 2024Gate Neurosciences Presents New Data and Insights Highlighting Unique Pharmacology of Synaptic Function Modulators at the 2024 ACNP Annual MeetingRead full post
December 3, 2024Gate Neurosciences and University of Pittsburgh Collaborate to Initiate Phase 2 Trial Combining Apimostinel with Digital Therapeutic for DepressionRead full post
May 15, 2024Gate Neurosciences to share new data and research on its synaptic function molecules with multiple posters at 2024 ASCP meetingRead full post
March 5, 2024Gate Neurosciences demonstrates zelquistinel preclinical efficacy and therapeutic potential in autism spectrum disorders in new peer-reviewed studyRead full post
January 24, 2024Gate Neurosciences announces clinical collaboration with beacon biosignals to advance precision EEG biomarkers in major depressive disorderRead full post
November 7, 2023Gate Neurosciences announces positive topline human EEG biomarker results demonstrating dose-dependent target activation in phase 1 study of apimostinelRead full post
Shekhar (2023): Aprison Lecture - Novel Approach to NMDA Modulation, Plasticity, Rapid Antidepressant Drugs
Duman (2020): Positive NMDAR modulation by Zelquistinel exerts rapid antidepressant-like effects via excitatory neurons
Zanos (2023): NMDAR activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine
Donello (2022): Zelquistinel is a novel oral NMDAR PAM exhibiting rapid and sustained antidepressant-like effects
